The News Review:

- Two international cancer research centres to set up in S’pore
- Ludwig Institute for Cancer Research to set up its first Asian branch…
- Daiichi Sankyoï¼ Lilly Announce New Prasugrel Head-to-Head Phase III…
- Jubilant rganosys: Buy
- Regado Biosciences Presents Positive Data From REG1 Anticoagulation…
- Harvard researcher wins prize for identifying destructive heart…
- Move to boost scientific research

Two international cancer research centres to set up in S’pore
Channel News Asia – Nov 4, 2007
“It is also a strong validation of Singapore’s growing importance as a global node in cancer research. These developments will boost our bio-medical science efforts and strengthen our capability in cancer research to bring new and novel therapeutics to cancer patients” he added. The global non-profit Ludwig Institute will set up a research branch in Singapore for translational and clinical research. It will be the institute’s first branch in Asia as the other nine are in Australia Europe and the Americas. But Mr Khaw also stressed the importance of health economics to ensure the system is sustainable and affordable for patients. Anti-cancer drugs such as herceptin for breast cancer cost tens of thousands of dollars in the United States he said this has led to spiralling insurance premiums that have become too high for some employers to cover leaving some patients unable to afford treatment. To fight cancer the minister stressed that not only more investment in clinical research is needed but also greater international collaboration to maximise synergies and the chances of success.

Ludwig Institute for Cancer Research to set up its first Asian branch…
eurekalert.org – Nov 4, 2007
In addition to strengthening Singapore’s capabilities in cancer research and clinical trials LICR’s strong international presence will expand Singapore’s global scientific network and increase Singapore’s population of clinician-scientists and investigators. As Lim Chuan Poh Chairman of A*STAR said “The proposal to establish the LICR in Singapore is in line with Singapore’s goal to be an international biomedical hub. ” Since last year A*STAR and the Singapore Health Ministry have launched programmes to build Singapore’s capabilities in translational and clinical research to complement its strength in basic biomedical research. “By taking discoveries at the ‘bench’ to be effected at the ‘bedside’ A*STAR and our partners aim to improve healthcare and benefit patients in Singapore and beyond” added Mr.

Daiichi Sankyoï¼ Lilly Announce New Prasugrel Head-to-Head Phase III…
é’èç – Nov 4, 2007
This plaque has the potential to rupture at any time and cause an arterial clot (thrombus) to form which can block oxygenated blood from reaching the heart muscle. Antiplatelet medications help to reduce the incidence of this acute thrombus formation. “The announcement of this study demonstrates our continued confidence in the clinical research surrounding prasugrel” said John Alexander M.

Jubilant rganosys: Buy
Hindu Business Line – Nov 4, 2007
The medicinal chemistry services business has seen revenue growth of 51 per cent year-on-year. Biosys which serves clients such as Eli Lilly deals with innovative informatics and structure-directed drug discovery solutions helping accelerate drug discovery. The last segment of the drug discovery business is Clinsys a full service clinical research organisation providing a broad range of clinical research services which support Phase I-IV drug development. This integrated approach helped Jubilant’s drug discovery and development business report Rs 80 crore as revenue for the first half of 2007-08. For the full year 2006-07 the same business reported Rs 65 crore. Jubilant targets revenues of Rs 175-200 crore for the full year. With outsourced life-science products and services comprising 55 per cent of total revenues in the first half of FY-08 the future seems bright as pricing pressure and the urgent need to improve pipeline are forcing pharma biotech and other life-science companies to increase outsourcing of products and services from low-cost locations such as India.

Regado Biosciences Presents Positive Data From REG1 Anticoagulation…
Free with registration – PR Newswire – AccessMyLibrary.com – Nov 4, 2007
The study results support RB007′s ability to reverse the anticoagulant effect of RB006 either completely or partially depending on the level of dosing of RB007. Consistent with previously reported Phase I results these data were presented by the Duke Clinical Research Institute at the American Heart Association’s 2007 Scientific Sessions currently being held in rlando Florida. Clinical researchers from the Duke Clinical Research. CPYRIGHT 2007 PR Newswire Association LLC.

Harvard researcher wins prize for identifying destructive heart…
eurekalert.org – Nov 4, 2007
The Survival and Ventricular Enlargement (SAVE) trial demonstrated the efficacy of ACE inhibitors to treat acute heart attack and chronic heart failure. “This historic trial paved the way for numerous other investigations expanding and elaborating on the effective use of these medications to improve survival and reduce morbidity” Jones said. Pfeffer who leads a large clinical research department is principal investigator of international trials testing novel approaches to reduce cardiovascular risk.

Move to boost scientific research
Hindu – Nov 4, 2007
It would also encourage scientists to work in the industry for three to four years in projects which would ultimately help in the creation of wealth. Kapil Sibal was talking to presspersons after laying the foundation for a clinical research facility for stem cells and regenerative medicine and national bio-safety level four containment facility for human infectious diseases. These facilities are to be established by the Centre for Cellular and Molecular Biology (CCMB) at Uppal here. Guidelines ready Replying to a question on the need to regulate research on stem cells he said the process was on and guidelines were already available on website of his Ministry. “We do not have many experts hence the need for having a public debate on the issue with a view to incorporating divergent points”. The Government had recently interlinked 40 institutions involved in research on stem cells he added.